Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 2Phase 1/2 2

Status

Completed 4Active not recruiting 2

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Non-Small-Cell Lung 32Breast Neoplasms 25Parkinson Disease 4, Autosomal Dominant Lewy Body 18Multiple Myeloma 13Neoplasms 12Leukemia, Myeloid, Acute 12Ovarian Neoplasms 10Neoplasm Metastasis 10Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Colorectal Neoplasms 8Melanoma 7Lymphoma, Non-Hodgkin 7Leukemia 7Stomach Neoplasms 6Recurrence 6Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Adenocarcinoma 5Purpura, Thrombocytopenic, Idiopathic 4Myelodysplastic Syndromes 4Lymphoma, Follicular 4Liver Neoplasms 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4

Interventions

Sorafenib 4lenvatinib 2tremelimumab 1durvalumab 1cabozantinib 1atezolizumab 1Ramucirumab 1Nivolumab 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Has announcements × Carcinoma, Hepatocellular × Clear all
NCT04039607 2026-04-06

CheckMate 9DW

Bristol-Myers Squibb

Phase 3 Active not recruiting
732 enrolled 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT03298451 2026-03-20

HIMALAYA

AstraZeneca

Phase 3 Active not recruiting
1,324 enrolled 31 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT03434379 2023-10-23

IMbrave150

Hoffmann-La Roche

Phase 3 Completed
558 enrolled 48 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular

NCT02435433 2023-01-20

REACH-2

Eli Lilly and Company

Phase 3 Completed
399 enrolled 22 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Eisai Inc.

Phase 3 Completed
954 enrolled 19 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01908426 2021-05-06

CELESTIAL

Exelixis

Phase 3 Completed
707 enrolled 20 charts 1 FDA
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡